WO2004039359A3 - Methode d'utilisation de derives de pyrimidine dans le traitement de troubles hyperproliferatifs - Google Patents

Methode d'utilisation de derives de pyrimidine dans le traitement de troubles hyperproliferatifs Download PDF

Info

Publication number
WO2004039359A3
WO2004039359A3 PCT/US2003/013784 US0313784W WO2004039359A3 WO 2004039359 A3 WO2004039359 A3 WO 2004039359A3 US 0313784 W US0313784 W US 0313784W WO 2004039359 A3 WO2004039359 A3 WO 2004039359A3
Authority
WO
WIPO (PCT)
Prior art keywords
proliferative disorders
hyper
manifacture
medicament
treatment
Prior art date
Application number
PCT/US2003/013784
Other languages
English (en)
Other versions
WO2004039359A2 (fr
Inventor
Jill E Wood
Yuanwei Chen
Barry Hart
Lin Yi
Jianqing Chen
Original Assignee
Bayer Pharmaceuticals Corp
Jill E Wood
Yuanwei Chen
Barry Hart
Lin Yi
Jianqing Chen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp, Jill E Wood, Yuanwei Chen, Barry Hart, Lin Yi, Jianqing Chen filed Critical Bayer Pharmaceuticals Corp
Priority to AU2003301758A priority Critical patent/AU2003301758A1/en
Publication of WO2004039359A2 publication Critical patent/WO2004039359A2/fr
Publication of WO2004039359A3 publication Critical patent/WO2004039359A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une méthode de traitement de troubles hyperprolifératifs consistant à administrer, à un patient nécessitant un tel traitement, une dose efficace d'un composé de formule (I), dans laquelle R est halo ou CF3, n vaut 0 ou 1, R1 est choisi indépendamment dans chaque cas dans le groupe constitué par halo, (C1-C3)alcoxy, et (C1-C3)alkylthiol, et m vaut 1 ou 2, ou un sel pharmaceutiquement acceptable dudit composé.
PCT/US2003/013784 2002-05-06 2003-05-02 Methode d'utilisation de derives de pyrimidine dans le traitement de troubles hyperproliferatifs WO2004039359A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003301758A AU2003301758A1 (en) 2002-05-06 2003-05-02 Use of pyrimidine derivates for the manifacture of a medicament for the treatment of hyper-proliferative disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37833002P 2002-05-06 2002-05-06
US60/378,330 2002-05-06

Publications (2)

Publication Number Publication Date
WO2004039359A2 WO2004039359A2 (fr) 2004-05-13
WO2004039359A3 true WO2004039359A3 (fr) 2004-07-22

Family

ID=32230080

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/013784 WO2004039359A2 (fr) 2002-05-06 2003-05-02 Methode d'utilisation de derives de pyrimidine dans le traitement de troubles hyperproliferatifs

Country Status (2)

Country Link
AU (1) AU2003301758A1 (fr)
WO (1) WO2004039359A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7989448B2 (en) 2005-01-19 2011-08-02 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US8557806B2 (en) 2002-07-29 2013-10-15 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US8835430B2 (en) 2002-02-01 2014-09-16 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0413018B8 (pt) 2003-07-30 2021-05-25 Rigel Pharmaceuticals Inc composto, e, uso de um composto
WO2006068770A1 (fr) 2004-11-24 2006-06-29 Rigel Pharmaceuticals, Inc. Composes de spiro-2, 4-pyrimidinediamine et leurs utilisations

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001064655A1 (fr) * 2000-03-01 2001-09-07 Astrazeneca Ab 2, 4-di(hetero-)arylamino (-oxy) pyrimidines substitues en 5, utilises comme agents antineoplasiques

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001064655A1 (fr) * 2000-03-01 2001-09-07 Astrazeneca Ab 2, 4-di(hetero-)arylamino (-oxy) pyrimidines substitues en 5, utilises comme agents antineoplasiques

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ABOU OUF A A ET AL: "Preparation of some methyl pyrimidines. Expected to be Antimetabilites", 1973, EGYPTIAN JOURNAL OF PHARMACEUTICAL SCIENCES, NATIONAL INFORMATION AND DOCUMENTATION CENTRE,, EG, PAGE(S) 180-195, ISSN: 0301-5068, XP009028502 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9346765B2 (en) 2002-02-01 2016-05-24 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US8835430B2 (en) 2002-02-01 2014-09-16 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US9018204B1 (en) 2002-02-01 2015-04-28 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US9416112B2 (en) 2002-02-01 2016-08-16 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US9913842B2 (en) 2002-02-01 2018-03-13 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US8557806B2 (en) 2002-07-29 2013-10-15 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US8211889B2 (en) 2005-01-19 2012-07-03 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US8211888B2 (en) 2005-01-19 2012-07-03 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US8476263B2 (en) 2005-01-19 2013-07-02 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US8785437B2 (en) 2005-01-19 2014-07-22 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US9266912B2 (en) 2005-01-19 2016-02-23 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US7989448B2 (en) 2005-01-19 2011-08-02 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US9532998B2 (en) 2005-01-19 2017-01-03 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses

Also Published As

Publication number Publication date
WO2004039359A2 (fr) 2004-05-13
AU2003301758A8 (en) 2004-05-25
AU2003301758A1 (en) 2004-05-25

Similar Documents

Publication Publication Date Title
AU2003225617A1 (en) Thiadiazolylpiperazine derivatives useful for treating or preventing pain
IN2015DN01132A (fr)
JO2311B1 (en) Alkyl inhibitors Ariel phosphodiesterase-4
WO2005056524A3 (fr) Agents therapeutiques pour traitement de la douleur
IL175716A (en) 2- (4-Bromo- or 4-Methyl-Phenylamino) -6-Oxo-1,6-Dihydropyridines and their use in drug preparation
NZ545506A (en) Therapeutic agents useful for treating pain
WO2004060882A8 (fr) Ligands des recepteurs cb 1/cb 2 et utilisation associee dans le traitement de la douleur
IL165264A (en) Protein kinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating protein kinase-associated diseases
WO2004072031A8 (fr) Composes d'amides substitues tri(cyclo)
GEP20043269B (en) Purine Derivatives, Method for Their Production and Composition Containing the Same
WO2005047244A3 (fr) Inhibition de recepteur fgfr3 et traitement de myelome multiple
NZ544009A (en) Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain
UA85708C2 (ru) Лекарственные комбинации, содержащие бензоксазины, для лечения заболеваний дыхательных путей
WO2005037798A3 (fr) Nouveaux composés
WO2004029031A3 (fr) Agents therapeutiques utiles dans le traitement de la douleur
WO2004037789A3 (fr) Derives de methylene uree
EP1251126A3 (fr) Derives de benzenesulfonyle a substitution fluor pour le traitment d'inflammation
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
PT1458393E (pt) Dicetopiperazinas substituídas como antagonistas da oxitocina
WO1999049854A3 (fr) Utilisation de dexmedetomidine pour la sedation dans une unite de soins intensifs
WO2004041802A8 (fr) Derives de 4(phenyl-piperazinyl-methyl) benzamide et utilisation de ceux-ci pour le traitement de la douleur et des troubles gastro-intestinaux
WO2005016327A3 (fr) Traitement de troubles du sommeil a l'aide d'inhibiteurs de la cholinesterase
WO2004039359A3 (fr) Methode d'utilisation de derives de pyrimidine dans le traitement de troubles hyperproliferatifs
WO2004052350A3 (fr) Methode de traitement de troubles moteurs a l'aide de derives de l'acide barbiturique
WO2007047893A3 (fr) Utilisation de dasatinib dans le traitement de metastase osseuse

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP